Univariate analysis of factors associated IC versus no IC
| IC | No IC | P value | |
| Total N | 67 | 90 | |
| Age (years), median (IQR) | 54 (50–57) | 55 (53–58) | 0.45 |
| Sex (male) | 48 (72%) | 33 (37%) | 0.63 |
| Stem cell transplant | 16 (24%) | 18 (20%) | 0.56 |
| Hematologic malignancy | 32 (48%) | 48 (53%) | 0.52 |
| Abdominal malignancy | 21 (31%) | 32 (36%) | 0.61 |
| Chemo<6 weeks | 33 (49%) | 57 (63%) | 0.10 |
| Abdominal radiation | 2 (3.0%) | 7 (7.8%) | 0.30 |
| Steroids | 8 (12%) | 17 (19%) | 0.28 |
| Nausea/vomiting | 41 (61%) | 41 (46%) | 0.06 |
| ANC (1000 cells/μL), median (IQR) | 6.4 (5.0–7.7) | 5.3 (3.8–6.9) | 0.36 |
| Platelets (1000/μL), median (IQR) | 171 (144–198) | 130 (108–152) | 0.02 |
| Length of stay (days), median (IQR) | 6 (3–9) | 6 (3–12) | 0.41 |
| ASA | |||
| I | 0 (0%) | 0 (0%) | 0.58 |
| II | 7 (12%) | 7 (7.8%) | |
| III | 48 (80%) | 84 (93%) | |
| IV | 19 (32%) | 40 (44%) | |
| V | 0 (0%) | 1 (1.1%) |
Chemo<6 weeks indicates chemotherapy received less than 6 weeks to presentation.
ANC, absolute neutrophil count; ASA, American Society of Anesthesiologists; IC, interval cholecystectomy; PCT, percutaneous cholecystostomy tube.